Effectiveness of Buspirone in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study
Middle East Journal of Digestive Diseases · 06.09.2021 · 13 (4) · 302-313
DOI: 10.34172/mejdd.2021.239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Middle East Journal of Digestive Diseases, online erschienen am 06.09.2021. Verfasst von Tarang Taghvaei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gut and Liver Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Functional dyspepsia (FD) is a relatively common disorder whose pathogenesis has yet been poorly understood. There are still debates concerning definitions and the best possible treatments for this disorder. We aimed to assess the effectiveness of buspirone, a 5-hydroxytryptamine (HT)1A agonist, in improving the symptoms and quality of life (QoL) as well as psychological dimensions in patients with FD. METHODS This study was a randomized, double-blinded, placebo-controlled trial performed on 30 patients with FD, residing in the city of Sari, northern Iran, from December 2017 to October 2018. Consecutive patients referring to a tertiary hospital with a clinical diagnosis of FD, according to the Rome IV criteria, were recruited. All patients were ethnically Persian and had normal upper endoscopy and negative histological evaluation results for any gastrointestinal disease or helicobacter pylori (H. pylori) infection while evaluating biopsy samples endoscopically. Exclusion criteria were being diagnosed with major psychiatric disorders, suicidal thoughts, recent treatments with psychoactive drugs, as well as major cognitive impairments. Patients were randomly assigned to receive either buspirone (n=18) or placebo (n=12) for two months. The first group received buspirone 5mg three times a day for the first month and 10mg three times a day for the second month. During the treatment course, the patients were advised to report any adverse reactions. Also, both groups were evaluated by three questionnaires [demographic characteristics form, the 36-Item Short-Form Health Survey (SF-36), The Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) and Hospital Anxiety and Depression Scale(HADS)] at the baseline and at the end of the 8th week by a blinded psychologist. Finally, data were analyzed using SPSS software (version 18). P values
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gut and Liver Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Sexual and reproductive health research center, Psychiatry and Behavioral Sciences Research Center, Addiction Institute, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Psychiatry, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Zitieren
APA
Taghvaei, T., Elyasi, F., Rahbar, Z., & Neyestani, F. (2021). Effectiveness of Buspirone in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. Middle East Journal of Digestive Diseases, 13(4), 302-313. https://doi.org/10.34172/mejdd.2021.239
Vancouver
Taghvaei T, Elyasi F, Rahbar Z, Neyestani F. Effectiveness of Buspirone in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. Middle East Journal of Digestive Diseases. 2021;13(4):302-313. doi:10.34172/mejdd.2021.239
BibTeX
@article{Taghvaei2021,
author = {Taghvaei, Tarang and Elyasi, Forouzan and Rahbar, Zahra and Neyestani, Farkhondeh},
title = {Effectiveness of Buspirone in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study},
journal = {Middle East Journal of Digestive Diseases},
year = {2021},
volume = {13},
number = {4},
pages = {302--313},
doi = {10.34172/mejdd.2021.239}
}
EUVIMED